The Hindu Business Line : Biocon cancer drug to enter Pakistan

Biocon's proprietary cancer drug BIOMAb-EGFR will enter the Pakistan through an exclusive marketing arrangement with Ferozsons Laboratories Ltd, the company said.

Ferozsons is rated by IMS as the No 1 oncology company in that country.

The successful debut of BIOMAb in India since mid-September 2006 has apparently elicited strong licensing interest for the drug in the region.

Pakistan's oncology market is put at $70 million (around Rs 315 crore) and it reports over 25,000 new cases of head and neck cancer alone each year, according to Globocan.

Monoclonal antibodies — on which BIOMAb is based — represent the therapeutics category growing at 30 per cent CAGR. Biocon is taking up global studies to extend BIOMAb's use to beyond head and neck cancer, to colorectal, lung cancer, glioma and pancreatic cancers.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
USFDA approval for Aurobindo drug

Panyam Cem to issue pref shares

IMA award for TNPL director

`CEOs conduct key for success'

HPCL in talks with Total for Vizag project

Momentive to put up silicone plant near Chennai

ONGC, Mittal group make efforts to revive joint venture

Innovative group, Syrian Chamber sign pact

Shell in talks with ONGC for coal gassification

Biocon cancer drug to enter Pakistan

Does philanthropy lead to profits?

Ministry moots new fund to revive sick floriculture units

ONGC confirms oil finds in KG and Mahanadi basins

Inox plans more multiplexes

L.M. Thapar - a pragmatic industrialist